Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease

NCT02768532 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Saint Etienne as lead sponsor.

NCT NCT02768532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02768532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Phase
Phase 4
Overall status
Terminated
Start date
July 1, 2016
Completion date
January 23, 2023
Enrollment
47 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease